Related Experiment Video
Updated: Aug 25, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Novel therapies for pancreatic adenocarcinoma
Simona M Pino1, Henry Q Xiong, David McConkey
1Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 426, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Abstract:
Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the disease remains a clinical challenge. Gemcitabine, the standard chemotherapy for pancreatic cancer, offers modest improvement of tumor-related symptoms and marginal advantage of survival. New approaches, alone and in combination with gemcitabine, are being developed to combat this cancer. In this article we review the current status of investigations into several classes of agents: matrix metalloproteinase inhibitors; farnesyl transferase inhibitors; epidermal growth factor receptor inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors; cyclooxygenase-2 inhibitors, and others. The scientific rationale, mechanism of action, and clinical trial data for these novel agents are discussed.
Insights
Pancreatic cancer remains challenging despite advances. This review explores novel therapeutic agents, including matrix metalloproteinase inhibitors and epidermal growth factor receptor inhibitors, to improve patient outcomes beyond standard gemcitabine chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Pancreatic cancer presents significant clinical challenges despite molecular and genetic understanding.
- Gemcitabine, the current standard chemotherapy, provides limited survival benefits and symptom improvement.
Purpose of the Study:
- To review novel therapeutic agents investigated for pancreatic cancer treatment.
- To discuss the scientific rationale, mechanisms of action, and clinical trial data for these emerging therapies.
Main Methods:
- Literature review of current investigations into novel pancreatic cancer agents.
- Analysis of data from clinical trials involving targeted therapies.
Main Results:
- Several classes of novel agents are under investigation, including matrix metalloproteinase inhibitors, farnesyl transferase inhibitors, epidermal growth factor receptor inhibitors (monoclonal antibodies and tyrosine kinase inhibitors), and cyclooxygenase-2 inhibitors.
- These agents are being evaluated both as monotherapies and in combination with gemcitabine.
Conclusions:
- Novel therapeutic strategies are crucial for overcoming the limitations of current pancreatic cancer treatments.
- Further research and clinical trials are necessary to establish the efficacy and safety of these agents in improving patient survival and quality of life.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...